Essex Savings Bank Trims Position in Danaher Co. (NYSE:DHR)

Essex Savings Bank reduced its holdings in Danaher Co. (NYSE:DHR) by 1.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 4,782 shares of the conglomerate’s stock after selling 76 shares during the period. Essex Savings Bank’s holdings in Danaher were worth $1,098,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Teachers Insurance & Annuity Association of America acquired a new stake in Danaher during the 3rd quarter worth about $39,000. MidAtlantic Capital Management Inc. purchased a new stake in shares of Danaher in the third quarter worth about $40,000. FSA Wealth Management LLC acquired a new stake in Danaher during the third quarter worth about $50,000. Darwin Wealth Management LLC purchased a new position in Danaher during the third quarter valued at approximately $55,000. Finally, Dunhill Financial LLC lifted its holdings in Danaher by 45.1% in the third quarter. Dunhill Financial LLC now owns 222 shares of the conglomerate’s stock valued at $62,000 after acquiring an additional 69 shares during the period. Institutional investors and hedge funds own 79.05% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently weighed in on DHR shares. KeyCorp lifted their target price on shares of Danaher from $290.00 to $310.00 and gave the company an “overweight” rating in a report on Wednesday, October 23rd. Evercore ISI lifted their price objective on shares of Danaher from $275.00 to $278.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. Scotiabank assumed coverage on shares of Danaher in a research note on Monday, December 23rd. They set a “sector perform” rating and a $265.00 target price on the stock. Stifel Nicolaus lifted their price target on Danaher from $250.00 to $265.00 and gave the company a “hold” rating in a research note on Wednesday, October 23rd. Finally, Wolfe Research upgraded Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price target on the stock in a research report on Thursday, October 31st. Six investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $286.80.

Danaher Stock Up 0.1 %

Shares of NYSE DHR opened at $237.78 on Thursday. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32. The company has a 50-day moving average of $235.27 and a 200 day moving average of $253.56. Danaher Co. has a 12-month low of $222.53 and a 12-month high of $281.70. The stock has a market cap of $171.74 billion, a PE ratio of 45.38, a P/E/G ratio of 4.32 and a beta of 0.83.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, beating the consensus estimate of $1.57 by $0.14. The firm had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.59 billion. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The business’s revenue for the quarter was up 3.1% on a year-over-year basis. During the same quarter last year, the firm earned $2.02 earnings per share. As a group, sell-side analysts predict that Danaher Co. will post 7.5 EPS for the current fiscal year.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Friday, December 27th will be issued a dividend of $0.27 per share. The ex-dividend date of this dividend is Friday, December 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.45%. Danaher’s dividend payout ratio is presently 20.61%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.